Kiniksa Pharmaceuticals sees strong growth from Arcalyst, aided by Medicare redesign. Learn about 2025 sales outlook & ...

Pharmaceutically made cannabidiol targeting myocarditis did not increase cardiovascular events in at-risk patients, a prospective study shows.

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Get Free Report)’s share price traded down 5.4% during trading on Thursday after an insider sold shares in the company.The stock traded as low as ...

These results highlighted that the revenue for Arcalyst, one of Kiniksa's products, surpassed expectations with a reported preliminary revenue of $416.4 million for FY24.

Roche has announced a pair of licensing deals with Poseida Therapeutics and Kiniksa Pharmaceuticals that bolster its pipeline in cancer and inflammatory diseases. The agreement with Poseida is by ...

The fusion protein Arcalyst (rilonacept), an IL-1 trap that acts as a soluble decoy receptor, is also marketed by Regeneron Pharmaceuticals, of Tarrytown, New York.